The aging prostate and the bother it causes
Lower urinary tract symptoms are common, the prostate is the usual suspect, and the whole art is matching the size of the gland and the size of the bother to the right step on the ladder — without missing the cancer, the stricture, or the bladder that has quietly given up.
The one-liner
Quantify bother with the IPSS, then climb the ladder: behavioral → α-blocker → add a 5-ARI if the gland is >30 cc → surgery for refractory symptoms or complications. Size picks the operation. Always remember a 5-ARI halves the PSA — double it.
“Benign prostatic hyperplasia” names a histologic process, but the patient in front of you has lower urinary tract symptoms — a weak stream, hesitancy, nocturia, the sense of incomplete emptying — and those are not the same thing. Plenty of large prostates cause no bother, and plenty of bothered men have small ones. The job is to measure the bother, size the gland, exclude the dangerous mimics, and then climb a ladder one rung at a time.
The frame: it's a plumbing problem with two components
The aging prostate obstructs in two ways. There is a static component — the physical bulk of the adenoma in the transition zone — and a dynamic component — smooth-muscle tone at the bladder neck and prostate, mediated by α₁-adrenergic receptors. That split is the whole basis of medical therapy: one drug class relaxes the dynamic tone, another shrinks the static bulk.
Measure the bother
The IPSS (International Prostate Symptom Score) turns a vague complaint into a number you can act on and follow:
- 0–7 — mild
- 8–19 — moderate
- 20–35 — severe
A separate quality-of-lifequestion matters as much as the total: a man with a “moderate” score who is miserable gets treated, and a man with a high score who is untroubled may simply be reassured.
What everyone gets wrong
Calling everything BPH. Before you treat, exclude what else makes a man void poorly: urethral stricture, prostate cancer, neurogenic bladder, a UTI, bladder stones, and the great masquerader, polyuria from undiagnosed diabetes or excess evening fluid. A DRE, a urinalysis, a PSA where appropriate, and a post-void residual sort most of this out. Hematuria or a hard nodule changes the conversation entirely.
The ladder
- Behavioral and watchful waiting — fluid timing, caffeine and alcohol moderation, treating constipation. The right answer for mild or untroubled symptoms.
- α-blocker (tamsulosin, alfuzosin, silodosin) — first-line drug therapy. It relaxes the dynamic component and works within days. Counsel about retrograde ejaculation and intra-operative floppy iris syndrome — the ophthalmologist needs to know before cataract surgery.
- Add a 5-α-reductase inhibitor (finasteride, dutasteride) when the gland is enlarged — > 30–40 cc. It shrinks the static bulk over 3–6 months, reduces the risk of acute retention and the need for surgery, but is slow and can dampen libido.
- Combination therapy for larger glands with significant symptoms — the MTOPS/CombAT logic: the two classes together beat either alone at preventing progression.
A 5-ARI roughly halves the PSA after six months. To read the cancer signal, double the measured value — and any rise on a 5-ARI is a red flag, not noise.
When the gland needs to come out (or be carved open)
The indications for surgery — the “refractory or complicated” list:
- Symptoms refractory to medical therapy, or intolerable side effects.
- Recurrent retention, recurrent UTIs, bladder stones, recurrent gross hematuria from the prostate.
- Renal impairment from chronic obstruction — the high-pressure chronic retention that backs up to the kidneys.
Size picks the operation
- TURP — the reference standard for glands roughly 30–80 cc.
- HoLEP (holmium laser enucleation) — size- independent; enucleates glands of any size with less bleeding, increasingly the answer for the very large prostate.
- Simple prostatectomy (open or robotic) — reserved for very large glands (> 80–100 cc) where enucleation isn’t available.
- Minimally invasive options (Rezūm water vapor, UroLift) — for men who want to preserve ejaculation or avoid the OR.
One anatomic landmark anchors the resection: the verumontanum. The external sphincter sits just distal to it, so the surgeon stops there — cut beyond it and you risk incontinence. It is the line you do not cross.
The detour: acute urinary retention
A man arrives unable to void, with a painfully full bladder. Decompress with a catheter, watch for post-obstructive diuresis in the high-volume drain, start an α-blocker, and attempt a trial without catheter in a few days. Failure of that trial is one of the cleaner indications to move toward surgery.
If you remember one thing
Match the rung to the patient: the bother (IPSS and quality of life) tells you whether to treat, and the gland size tells you how — which drug to add and, eventually, which operation. And never forget what the 5-ARI does to the PSA, because that is how a missed cancer hides inside a BPH chart.